The most compelling results were found combining Mateon's CA4P with an anti-CTLA4 antibody in an EMT-6 mammary model. In this study, 7 of 8 mice receiving the combination were tumor free at the study's completion, compared to 1 of 8 in the CA4P monotherapy arm and 2 of 8 in the anti-CTLA4 antibody monotherapy arm.
Three of four follow-up studies also demonstrated that CA4P combined with immune oncology agents delayed tumor growth. These studies were conducted in a larger tumor EMT-6 mammary model, a C3H mammary model and a CT26 colon model. The results provide additional supportive evidence that CA4P enhances anti-CTLA4 antibody activity, as well as initial evidence that CA4P enhances anti-PD-1 and PD-L1 activity.
"We have seen in numerous earlier studies that CA4P, via vascular disruption, induces rapid and extensive necrotic tumor cell death," stated
Mateon reminds investors that a webcast of today's presentation at the 19th Annual BIO CEO & Investor Conference at
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
Safe Harbor Statement
Certain statements in this news release, including, but not limited to, those concerning the pre-clinical data on the combination of CA4P with checkpoint inhibitors, the potential significance of this data and its relation to other clinical and pre-clinical studies are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to: the uncertainties as to the future success of ongoing and planned clinical trials; the unproven safety and efficacy of products under development or that may be developed in the future; and the sufficiency of the Company's cash resources to conduct and complete future clinical and pre-clinical trials. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon's reports to the
CONTACTS Investors: firstname.lastname@example.org 650-635-7000 Media:
JPA Health Communications Nic DiBellanic@jpa.com 617-945-5183
News Provided by Acquire Media